ADVERTISEMENT
2 /3 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Business

Novartis Gets Access To Israeli Drugs

by Rick Mullin
December 22, 2014 | APPEARED IN VOLUME 92, ISSUE 51

The Israeli biotech company BioLineRx has joined with Novartis to develop and commercialize drug candidates that come from academic labs and biotech firms in Israel. Novartis will evaluate projects identified by BioLineRx for codevelopment and potential licensing. The drug firm will make a $10 million investment in BioLineRx and pay other fees upon selection of projects for clinical development. The companies plan to develop up to three programs.

X

Article:

This article has been sent to the following recipient:

Leave A Comment

*Required to comment